Cangene Awarded Biodefence Contract for Anthrax Immune Globulin (AIGIV) by the U.S. Government

barbara.lempert

TSX: CNJ

Readers are referred to the cautionary notes regarding Forward-looking Information and non-IFRS Financial Measures at the end of this release. Unless noted otherwise, all dollar amounts are in dollars.

TORONTO, Sept. 19, 2013 /CNW/ – Corporation () announced today that it has been a multiple award indefinite delivery/indefinite quantity to potentially provide its Intravenous () to the U.S. Department of Health and Human Services (HHS) for the U.S. ’s program.  Cangene’s AIGIV, a hyperimmune antibody product specific for Bacillus anthracis bacteria, was first accepted into the U.S. Strategic National Stockpile in 2007.

Under the terms of the five-year contract, Cangene could be awarded delivery orders for the collection and storage of anti-Anthrax human plasma, for the manufacturing of bulk drug substance and AIGIV final drug product.  The contract’s work statement has a total potential maximum value of approximately $ 264 million to Cangene.

In conjunction with the contract award, Cangene was awarded the first task/delivery order under the contract.  The order is for the collection and storage of anti-Anthrax human plasma sufficient to manufacture 10,000 doses of bulk drug substance or final drug product.  This order is expected to generate aggregate revenue of approximately $ 63 million for Cangene for fiscal years 2014, 2015 and 2016, which is included in the aforementioned approximate total potential maximum value of the contract’s work statement.

John A. Sedor, President and CEO of Cangene, said: “We are proud to have been selected by the U.S. government for this important medical countermeasure.  This marks our second major biodefence contract this year, with the extension of our VIGIV contract with the Centers for Disease Control and Prevention that we announced earlier this month, underscoring our leadership in biodefence…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS